This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario
by Zacks Equity Research
LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.
Abbott's (ABT) Heart Failure Device Study Outcome Favorable
by Zacks Equity Research
Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
Medtronic's (MDT) Micra TPS CED Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Micra TPS new study data supports the relationship of a lower risk of complications with leadless pacing.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.
Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges
by Zacks Equity Research
According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.
7 Value Stocks to Unlock Gains Using Price-to-Book Ratio
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Walgreens (WBA) Provides Flu Shots Nationwide for Ages 3 & More
by Zacks Equity Research
Walgreens (WBA) is ready to co-administer COVID-19 vaccines and flu shots anticipating COVID-19 boosters in September.
Omnicell (OMCL) Enhances Medication Management With New Release
by Zacks Equity Research
Omnicell's (OMCL) Summer 2021 Release offers greater platform deployment options, providing customers better flexibility and improving time to value for strategic initiatives.
Abbott's (ABT) Base Volume Rebounds, Lowered View Concerns
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business. However, high debt level remains a woe.
Quest Diagnostics (DGX) Acquires Florida-Based NLS Assets
by Zacks Equity Research
Quest Diagnostics (DGX) expects the acquisition to broaden the company's spectrum in diagnostic innovation and insights.
Medtronic (MDT) Receives FDA Nod for Evolut FX TAVR System
by Zacks Equity Research
Medtronic's (MDT) Evolut FX TAVR system offers hemodynamic and durability benefits of the Evolut platform with new product and procedure enhancements.
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Hologic (HOLX) Acessa Procedure Gets Anthem Insurance Coverage
by Zacks Equity Research
Hologic's (HOLX) Acessa Procedure's new coverage upholds Laparoscopic Radiofrequency Ablation for women suffering from uterine fibroids.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on robust segmental growth and raised 2021 guidance.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.
Masimo's (MASI) Noninvasive Continuous PVi Favored by New Study
by Zacks Equity Research
Masimo (MASI) reports study findings that will aid clinicians in getting meaningful information with respect to monitoring the volume status in critically ill patients with spontaneous breathing.
Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic
by Zacks Equity Research
Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid BSI Nano Group growth potential and raised 2021 financial guidance.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.
Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion
by Zacks Equity Research
Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and raised 2021 outlook.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.
ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization
by Zacks Equity Research
ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.